Regeneron Pharmaceuticals Inc.

REGN

Held by 3 specialist biotech funds

High Convergence

3 funds opened new positions. Next phase2 readout (Alirocumab): Nov 2011. Short interest: 3.0% of float.

BiotechnologyCEO: Leonard S. SchleiferIPO: 1991Website ↗

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Catalysts

Phase 2PositiveQ4 2009Intravitreal Aflibercept InjectionDiabetic Macular EdemaNCT00789477

Primary: Change in BCVA From Baseline to Week 24 - Last Observation Carried Forward (LOCF) (At week 24)Enrollment:221/221Sites: 47RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ2 2010REGN475SciaticaNCT00991172

Primary: Sciatic pain between baseline and end of week 4 (4 weeks)Enrollment:159/159Sites: 30RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q4 2010PlaceboGoutNCT00958438

Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 113 (Week 16) (Day 1 to Day 113 (Week 16))Enrollment:248/248Sites: 61RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ1 2011REGN475/SAR164877Abdominal Pain UpperNCT01001923

Primary: Mean change from baseline in pain intensity as assessed by Pain Intensity Numeric Rating Scale (PI-NRS) (baseline and 4 weeks after injection)Enrollment:15/15Sites: 17RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ2 2011AfliberceptAdvanced Carcinoma, Non-small Cell Lung CancerNCT00794417

Primary: Phase 1: Recommended Dose of Aflibercept for Phase 2 (Phase 1: Baseline up to 315 Days)Enrollment:60/60Sites: 15NON_RANDOMIZED, TREATMENT

Phase 2PositiveQ4 2011AlirocumabHypercholesterolemiaNCT01266876

Primary: Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis (From Baseline to Week 12 (LOCF))Enrollment:77/77Sites: 22RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ4 2012DupilumabAtopic DermatitisNCT01639040

Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) (Baseline up to the end of study (up to Day 78))Enrollment:31/31Sites: 13RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeQ2 2013REGN846Pruritus, Atopic DermatitisNCT01605708

Primary: Clinical Activity (Week 2)Enrollment:19/19Sites: 14RANDOMIZED, TRIPLE, TREATMENT

Phase 3NegativeQ2 2013RilonaceptGoutNCT01459796

Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) (Day 1 to Day 392 (Week 56))Enrollment:220/220Sites: 74RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ3 2013Intravitreal Aflibercept Injection 2mgNeovascular Age-related Macular DegenerationNCT00964795

Primary: Safety and Tolerability of Intravitreal Aflibercept Injection in Participants With Neovascular AMD (Baseline (day 1) through end of treatment (Week 180))Enrollment:323/323Sites: 124NA, TREATMENT

Phase 3PositiveQ2 2014AlirocumabHypercholesterolemiaNCT01730053

Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis (From Baseline to Week 24)Enrollment:305/305Sites: 93RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ2 2014DupilumabAtopic DermatitisNCT01859988

Phase 2PositiveQ4 2014DupilumabAtopic Dermatitis (AD)NCT01979016

Primary: Percent Change From Baseline in the Eczema Area Severity Index Score (EASI) to Week 16 (Baseline to Week 16)Enrollment:54/54Sites: 4RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2015DupilumabAtopic DermatitisNCT02260986

Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 (Baseline to Week 16)Enrollment:740/740Sites: 148RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ3 2015DupilumabAtopic DermatitisNCT02210780

Primary: Percentage of Participants With a Positive Response (≥4-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 16 (Week 16)Enrollment:194/194Sites: 42RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ4 2015DupilumabDermatitis, AtopicNCT02277743

Phase 3PositiveQ1 2016PlaceboHeterozygous Familial HypercholesterolemiaNCT02326220

Primary: Change in Standardized Rate of Apheresis Treatments From Week 7 to Week 18 (Week 7 to Week 18 (before start of open-label treatment))Enrollment:62/62Sites: 13RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ1 2016DupilumabAtopic DermatitisNCT02407756

Phase 3Q1 2016REGN475Osteoarthritis, Knee, Osteoarthritis, HipNCT02447276

Primary: The primary endpoint in the study is the change from baseline to week 16 in the Western Ontario and McMaster Osteoarthritis Index (WOMAC) pain subscale score. (Baseline to week 16)Enrollment:421/421Sites: 72RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ3 2016DupilumabAtopic DermatitisNCT02395133

Primary: Difference Between Current Study Baseline and Week 36 in Percent Change in EASI From Parent Study Baseline (NCT02277743 and NCT02277769) (Baseline (Parent Study), Baseline (Current Study) and Week 36 (Current study))Enrollment:422/422RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeQ3 2016REGN2176-3Neovascular Age-Related Macular DegenerationNCT02418754

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye at Week 12 (Baseline, Week 12)Enrollment:505/505Sites: 84RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ4 2016AlirocumabHypercholesterolemia, Heterozygous Familial HypercholesterolemiaNCT01576484

Primary: Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Death (Baseline (Day 1 of current study) to end of study (Week 218))Enrollment:58/58Sites: 14NON_RANDOMIZED, TREATMENT

Phase 3NegativeQ1 2017FasinumabLow Back PainNCT02620020

Phase 2PositiveQ1 2017DupilumabEosinophilic EsophagitisNCT02379052

Primary: Absolute Change From Baseline in Straumann Dysphagia Instrument (SDI) Patient Reported Outcome (PRO) Total Score at Week 10 (Baseline, Week 10)Enrollment:47/47Sites: 14RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ2 2019evinacumabHomozygous Familial HypercholesterolemiaNCT03399786

Phase 3PositiveQ2 2019DupilumabDermatitis, AtopicNCT03345914

Phase 3NegativeQ4 2019FasinumabOsteoarthritis, Knee, Osteoarthritis, HipNCT03304379

Primary: Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Placebo (Baseline up to Week 24)Enrollment:1,650/1,650Sites: 71RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ4 2019REGN1908-1909Cat Allergy, Mild AsthmaNCT03838731

Primary: Time to Early Asthmatic Response (EAR) Upon Controlled Cat Allergen Challenge in an Environmental Exposure Unit (EEU) on Day 8 (Day 8)Enrollment:56/56Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2MixedQ1 2020FasinumabOsteoarthritis, Knee, Osteoarthritis, HipNCT03691974

Primary: Change From Baseline in Peroneal Motor Nerve Conduction Velocity at Week 16 (Baseline, Week 16)Enrollment:180/180Sites: 47RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ1 2020REGN3500Atopic DermatitisNCT03738423

Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16 (Week 16)Enrollment:129/129Sites: 89RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ2 2020REGN5069Osteoarthritis of the Knee, PainNCT03956550

Phase 2PositiveQ2 2020EvinacumabHypercholesterolemiaNCT03175367

Primary: Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 16 (Intent-to-Treat [ITT] Estimand) (Baseline and Week 16)Enrollment:272/272Sites: 95RANDOMIZED, TRIPLE, TREATMENT

Phase 3NegativeQ3 2020SarilumabCOVID-19NCT04315298

Phase 2Q3 2020REGN2477+REGN1033Sporadic Inclusion Body MyositisNCT03710941

Primary: Percent change in total lean mass as measured by dual-energy X-ray absorptiometry (DXA) (Up to Week 20)0RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ4 2020FasinumabOsteoarthritis of the Knee or HipNCT02683239

Primary: Number of Participants With Any Treatment-Emergent Adverse Event (TEAE) (Baseline up to week 52)Enrollment:5,331/5,331Sites: 149RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ2 2021REGN10933+REGN10987 combination therapyCOVID-19NCT04426695

Phase 2PositiveQ2 2021afliberceptNeovascular (Wet) Age-Related Macular DegenerationNCT04126317

Phase 2PositiveQ2 2021REGN3918Paroxysmal Nocturnal Hemoglobinuria (PNH)NCT03946748

Primary: Percentage of Participants Who Achieved Adequate Control of Intravascular Hemolysis (Week 4 through Week 26)Enrollment:24/24Sites: 12NA, TREATMENT

Phase 3NegativeQ3 2021REGN2810/ipiNon-small Cell Lung CancerNCT03515629

Primary: Progression-Free Survival (PFS) as Assessed by a Blinded Independent Review Committee (IRC) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessments (Up to 32 months)Enrollment:5/5Sites: 3RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2021SDREGN2810Advanced Non-Small Cell Lung CarcinomaNCT03430063

Primary: Objective Response Rate (ORR) in Participants Whose Tumors Express Programmed Cell Death Ligand 1 (PD-L1) in <50% of Tumor Cells (From date of randomization up to 41 months)Enrollment:28/28Sites: 31RANDOMIZED, TREATMENT

Phase 2Q1 2022PlaceboGeneralized LipodystrophyNCT04159415

Primary: Absolute Change From Baseline in Participants With Elevated Baseline Hemoglobin A1c (HbA1c ≥7%) at Week 8 (Baseline, Week 8)Enrollment:16/16Sites: 8RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ1 2022casirivimab+imdevimab combination therapyCOVID-19NCT04425629

Primary: Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) - [Ph1, Ph2, Ph3 Cohort 1 - Cohort 3] (Through Day 29)Enrollment:10,078/10,078Sites: 114NA, TREATMENT

Phase 3ApprovedQ1 2022EvinacumabHomozygous Familial HypercholesterolemiaNCT04233918

Phase 3Q1 2022garetosmabFibrodyplasia Ossificans Progressiva (FOP), Heterotopic Ossification (HO)NCT04577820

Phase 3NegativeQ2 2022REGN3918Paroxysmal Nocturnal HemoglobinuriaNCT04162470

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs (Baseline up to Week 104)Enrollment:24/24Sites: 14NA, TREATMENT

Phase 3Q2 2022afliberceptDiabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes MellitusNCT04429503

Phase 3Q2 2022DupilumabAtopic DermatitisNCT01949311

Phase 2PositiveQ4 2022PozelimabParoxysmal Nocturnal HemoglobinuriaNCT04811716

Phase 2Q4 2022CemiplimabHodgkin LymphomaNCT04373083

Phase 2NegativeQ1 2023evinacumabHypertriglyceridemiaNCT04863014

Phase 2Q3 2023Pexastimogene Devacirepvec (Pexa-Vec)Renal Cell CarcinomaNCT03294083

Primary: Maximum tolerated dose(MTD) / Maximum feasible dose (MFD) (36 days after first treatment)Enrollment:89/89Sites: 18RANDOMIZED, TREATMENT

Phase 2PositiveQ4 2023cemiplimabAdvanced Cutaneous Squamous Cell CarcinomaNCT02760498

Phase 2NegativeQ4 2023REGN4461Familial Partial Lipodystrophy, Metabolic AbnormalitiesNCT05088460

Primary: Percent Change From Baseline to Week 12 in Fasting Serum Triglyceride (TG) (Cohort A) (Baseline to week 12)Enrollment:20/20Sites: 8RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ1 2024CMP-001Squamous Cell Carcinoma of Head and NeckNCT04633278

Phase 2NegativeQ1 2024CMP-001Melanoma, Advanced Melanoma, Metastatic MelanomaNCT04698187

Phase 2PositiveQ2 2024REGN9933Venous ThromboembolismNCT05618808

Phase 3PositiveQ3 2024dupilumabBullous PemphigoidNCT04206553

Phase 2NegativeQ4 2024vidutolimodMerkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell CarcinomaNCT04916002

Phase 3Q1 2025REGN2810Non-small Cell Lung CancerNCT03409614

Phase 2Q1 2025cemiplimabNon-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell CarcinomaNCT03916627

Phase 2Q2 2025REGN5459Relapsed Multiple Myeloma, Refractory Multiple MyelomaNCT04083534

Phase 2Q2 2025VV1Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal CancerNCT04291105

Phase 3Jul 8, 2025Pozelimab + CemdisiranGeneralized Myasthenia GravisNCT05070858

Phase 3Jul 17, 2025GaretosmabFibrodysplasia Ossificans ProgressivaNCT05394116

Phase 3Q3 2025Aflibercept 8 mgNeovascular Age-Related Macular Degeneration, Diabetic Macular EdemaNCT06491914

Phase 2Sep 16, 2025Non-small Cell Lung Cancer (NSCLC)NCT05553834

Phase 2Q3 2025CemiplimabCutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell CarcinomaNCT04050436

Phase 2NegativeQ4 2025REGN5381Uncontrolled HypertensionNCT06833190

Phase 2Q4 2025CemiplimabMetastatic Solid TumorNCT04706715

Phase 2Dec 15, 2025TirzepatideObesityNCT06373146

Phase 3Dec 29, 20258 mg aflibercept (BAY 86-5321) (High Dose)Diabetic Macular EdemaNCT06422507

Phase 2Dec 31, 2025Aspirin ChallengeAspirin-exacerbated Respiratory DiseaseNCT05031455

Phase 2Jan 31, 2026DupilumabPruritisNCT06226610

Phase 2Q1 2026UbamatamabRecurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal CancerNCT03564340

Phase 2Q1 2026REGN7544Sepsis-Induced HypotensionNCT06608901

Phase 2Feb 18, 2026DupilumabEosinophilic Gastritis (Eo G), Eosinophilic Duodenitis (Eo D), Eosinophilic Gastrointestinal Disease (EGID)NCT05831176

Phase 3Mar 16, 2026FianlimabMelanomaNCT05352672

Phase 2Mar 20, 2026REGN7544Postural Orthostatic Tachycardia Syndrome (POTS)NCT06593600

Phase 2Q1 2026REGN9933Venous ThromboembolismNCT06299111

Phase 2Apr 1, 2026Sarilumab SAR153191 (REGN88)Juvenile Idiopathic ArthritisNCT02991469

Phase 2Q2 2026FianlimabResectable Non-small Cell Lung CancerNCT06161441

Phase 2Apr 30, 2026CemiplimabColon CancerNCT05961709

Primary: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 (Through study completion; an average of 1 year)Enrollment:50/50Sites: 5NA, TREATMENT

Phase 2May 15, 2026DupilumabColitis UlcerativeNCT05731128

Phase 2Q2 2026Trevogrumab-Part AObesityNCT06299098

Primary: Incidence of treatment-emergent adverse events (TEAEs) (Baseline to week 7)Enrollment:1,005/1,005Sites: 60RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Jun 8, 2026DupilumabLichen Simplex ChronicusNCT06687980

Phase 2Q2 2026cemiplimabCutaneous Squamous Cell CarcinomaNCT06384820

Phase 3Jun 8, 2026DupilumabLichen Simplex ChronicusNCT06687967

Phase 2Q3 2026OdronextamabB-cell Non-Hodgkin Lymphoma (B-NHL)NCT03888105

Phase 3Q3 2026mibavademabGeneralized LipodystrophyNCT06548100

Phase 3Q3 2026FianlimabMelanomaNCT05608291

Phase 2Aug 7, 2026Itepekimab (SAR440340)Chronic Rhinosinusitis Without Nasal PolypsNCT06691113

Phase 3Q4 2026DupilumabAtopic DermatitisNCT02612454

Phase 3Q4 2026RavulizumabParoxysmal Nocturnal HemoglobinuriaNCT05133531

Phase 2Q4 2026cemiplimabMelanomaNCT06190951

Phase 2Q4 2026REGN7075Advanced Solid TumorsNCT04626635

Phase 2Q4 2026OlatorepatideOverweight or ObesityNCT07431086

Phase 2Q4 2026REGN2810Prostate Cancer MetastaticNCT03951831

Phase 2Q4 2026DupilumabAsthma, AllergicNCT05720325

Phase 3Dec 1, 2026Itepekimab (SAR440340)Chronic Obstructive Pulmonary DiseaseNCT06208306

Phase 2Q4 2026REGN7999Non-Transfusion Dependent Beta-Thalassemia (NTDT)NCT06421636

Phase 2Q4 2026AlirocumabHypercholesterolemiaNCT07477704

Phase 2Q4 2026DegarelixProstate CancerNCT04989946

Phase 2Dec 31, 2026DupilumabAsthmaNCT05347771

Phase 2Q4 2026CemiplimabCarcinoma, Non-Small-Cell LungNCT06623656

Phase 2Jan 2, 2027OdronextamabFollicular Lymphoma, LymphomaNCT07128641

Phase 3Jan 8, 2027Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal PolypsNCT06834360

Phase 3Jan 8, 2027Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal PolypsNCT06834347

Phase 2Q1 2027REGN7508Atrial Fibrillation (AF)NCT07175428

Phase 3Q1 2027REGN7508Venous Thromboembolism (VTE)NCT07015905

Phase 3Q1 2027REGN5713Allergic ConjunctivitisNCT07309432

Primary: Ocular itch score in participants receiving REGN5713-5715 compared to placebo (At Day 8 post-Conjunctival Allergen Challenge (CAC))Enrollment:Target 350Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2027fianlimabMelanomaNCT06246916

Phase 2Q1 2027REGN5668Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal CancerNCT04590326

Phase 2Q2 2027S095018Non-small Cell Lung Cancer (NSCLC)NCT06162572

Phase 2May 15, 2027CemiplimabLocally Recurrent Oral Cavity Squamous Cell CarcinomaNCT06448026

Phase 2Q2 2027ALN-CIDEBMetabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated SteatohepatitisNCT06836609

Phase 3Q2 2027REGN7508Symptomatic Venous Thromboembolism (VTE)NCT07213778

Phase 2Q2 2027CemiplimabNon-Small Cell Lung CancerNCT06465329

Phase 3Q2 2027MibavademabMonogenic ObesityNCT07220772

Phase 2Q2 2027SNS-101 (anti-VISTA)Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck CancerNCT05864144

Phase 2Jun 30, 2027CemiplimabHPV-Related Squamous Cell CarcinomaNCT04988074

Phase 3Q3 2027nexiguran ziclumeranNeuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative DiseaseNCT06672237

Primary: Modified Neuropathy Impairment Score +7 (mNIS+7) (18 Months)Enrollment:Target 60Sites: 14RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2027ALN-PNPHealthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)NCT05648214

Phase 2Q3 2027MibavademabFunctional Hypothalamic Amenorrhea (FHA)NCT07235917

Primary: Change from the highest serum estradiol observed during a 28-day period (Baseline to month 6)Enrollment:Target 34Sites: 5RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2027ErveboEbola Virus DiseaseNCT05202288

Phase 2Q3 2027CemiplimabNSCLC, Locally AdvancedNCT06865339

Phase 2Aug 31, 2027LinvoseltamabMultiple MyelomaNCT06376526

Phase 2Q3 2027ALN-ANG3Diabetic Kidney Disease (DKD)NCT07271186

Phase 3Q3 2027fianlimabAdvanced Non-Small Cell Lung CancerNCT05785767

Phase 2Q3 2027FianlimabAdvanced MelanomaNCT06594991

Phase 3Oct 20, 2027Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal PolypsNCT07484230

Phase 3Oct 28, 2027DupilumabPrurigo NodularisNCT06293053

Phase 2Nov 3, 2027DupilumabAlopecia AreataNCT05551793

Phase 2Q4 2027REGN5678Metastatic Castration-Resistant Prostate Cancer (m CRPC), Clear Cell Renal Cell Carcinoma (cc RCC)NCT03972657

Phase 2Q4 2027VonsetamigChronic Kidney Disease (CKD)NCT05092347

Primary: Incidence of adverse event(s) of interest (AEI) from the first dose through end of the safety observation period (Up to approximately 6 weeks)Enrollment:Target 56Sites: 10NA, TREATMENT

Phase 3Q4 2027PozelimabAge-related Macular Degeneration (AMD), Geographic Atrophy (GA)NCT06541704

Phase 2Dec 1, 2027CemiplimabLung Cancer (NSCLC)NCT07450183

Phase 2Q4 2027Cemiplimab-RwlcNon-small Cell Lung Cancer Stage IIINCT06449313

Phase 3Dec 31, 2027CemiplimabRecurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8NCT06616584

Phase 3Q4 2027NTLA-2001Transthyretin Amyloidosis (ATTR) With CardiomyopathyNCT06128629

Phase 3Q1 2028CemiplimabCutaneous Squamous Cell CarcinomaNCT03969004

Phase 2Q1 2028OlatorepatideOverweight or ObesityNCT07685808

Phase 2Q1 2028BNT116Advanced Non-Small Cell Lung CancerNCT05557591

Phase 2Q1 2028Encorafenib + BinimetinibMelanoma BRAF V600E/K Mutated, Melanoma and Brain MetastasesNCT06887088

Phase 2Q1 2028CemiplimabColon and Rectal CancerNCT07433673

Phase 3Q1 2028OdronextamabFollicular Lymphoma (FL)NCT06091254

Phase 2Q1 2028REGN13335Pulmonary Arterial Hypertension (PAH)NCT07318597

Phase 3Q1 2028OdronextamabDiffuse Large B-cell Lymphoma (DLBCL)NCT06091865

Phase 2Q1 2028CemiplimabBladder Urothelial CarcinomaNCT07414992

Phase 2Q1 2028CemiplimabHead and Neck Squamous Cell CarcinomaNCT06855212

Phase 2Apr 10, 2028OdronextamabRecurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular LymphomaNCT06784726

Phase 2Q2 2028ALN-HSDMetabolic Dysfunction-Associated Steato Hepatitis (MASH)NCT05519475

Phase 2Q2 2028Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]Colon CancerNCT07224022

Phase 3Q2 2028MibavademabGeneralized LipodystrophyNCT07220785

Phase 3Q2 2028OdronextamabB-Cell Non-Hodgkin Lymphoma (B-NHL)NCT06230224

Primary: Event-free survival (EFS) as assessed by independent central review (ICR) (Assessed up to 3 years)Enrollment:Target 216Sites: 101RANDOMIZED, TREATMENT

Phase 2Q2 2028CemiplimabPleural MesotheliomasNCT07234058

Phase 2Q2 2028CemiplimabColorectal CancerNCT06205836

Phase 2Jun 1, 2028CemiplimabColo-rectal CancerNCT07058012

Phase 2Q2 2028FDC fianlimab+cemiplimabHead and Neck Squamous Cell Carcinoma (HNSCC)NCT06769698

Phase 3Q2 2028dupilumabEosinophilic Esophagitis (Eo E)NCT07112378

Phase 2Q2 2028REGN7041Active Noninfectious Uveitis Affecting the Posterior SegmentNCT07218770

Phase 2Q2 2028UbamatamabOvarian Cancer, Fallopian Tube Cancer, Primary Peritoneal CancerNCT06787612

Phase 2Q2 2028MotixafortidePancreatic Cancer, Adenocarcinoma of the Pancreas, AdenocarcinomaNCT04543071

Phase 2Jun 30, 2028LinvoseltamabRecurrent Multiple Myeloma, Refractory Multiple MyelomaNCT07181941

Phase 2Jul 31, 2028UbamatamabSMARCB1-Deficient MalignanciesNCT06444880

Phase 2Q3 2028Cemiplimab Plus GemcitabinePancreatic Ductal Adenocarcinoma (m PDAC)NCT06790602

Phase 2Q3 2028LinvoseltamabRelapsed/Refractory Systemic Light Chain AmyloidosisNCT06292780

Phase 2Sep 1, 2028SAR444881Solid TumorsNCT06651593

Phase 3Q4 2028PozelimabParoxysmal Nocturnal HemoglobinuriaNCT05744921

Phase 2Q4 2028CemiplimabBasal Cell Carcinoma (BCC), First Line TreatmentNCT06981325

Phase 3Q4 2028garetosmabFibrodysplasia Ossificans Progressiva (FOP)NCT07559513

Phase 3Dec 12, 2028Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal PolypsNCT07424144

Phase 3Dec 21, 2028DupilumabWheezing, AsthmaNCT06191315

Phase 2Q4 2028GemcitabineBladder Cancer, Muscle-Invasive Bladder CarcinomaNCT06571708

Phase 2Q4 2028cemiplimabCutaneous Basal Cell CarcinomaNCT07251413

Phase 3Q1 2029Dupilumab Prefilled SyringeAsthma ControlNCT07309614

Phase 2Q1 2029ALN-CIDEBMetabolic Dysfunction-Associated Steatohepatitis (MASH)NCT07631637

Phase 2Q1 2029Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)NCT05788536

Phase 3Q1 2029REGN7508Atrial Fibrillation (AF)NCT07430956

Phase 3Q1 2029CemiplimabNon-Small Cell Lung CancerNCT06931717

Phase 3Q2 2029LinvoseltamabRelapsed and/or Refractory Multiple Myeloma (RRMM)NCT07222761

Phase 2Q2 2029CemiplimabCutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, NeoplasmsNCT05878288

Phase 3Q2 2029REGN-2CatAllergic ConjunctivitisNCT07675811

Phase 3Q2 2029REGN7508Venous Thromboembolism (VTE)NCT07697599

Phase 2Q3 2029REGN22530Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)NCT07675824

Phase 3Q3 2029OdronextamabFollicular Lymphoma (FL)NCT06097364

Phase 3Q3 2029REGN7508Peripheral Artery Disease (PAD)NCT07318610

Phase 2Q3 2029Cemiplimab 350 MG Intravenous SolutionClear Cell Renal Cell CarcinomaNCT07223541

Phase 3Q3 2029REGN7508Atrial Fibrillation (AF)NCT07626411

Phase 2Q4 2029Fianlimab+cemiplimabMelanomaNCT06848088

Phase 2Q4 2029ALN-CFBParoxysmal Nocturnal Hemoglobinuria (PNH), Persistent AnemiaNCT07187401

Phase 2Q4 2029FianlimabAdvanced Renal Cell Carcinoma (a RCC), Metastatic Renal Cell Carcinoma ( m RCC), Clear Cell Renal Cell Carcinoma (cc RCC)NCT07188896

Phase 2Dec 31, 2029Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cyclesMerkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Neoadjuvant ImmunotherapyNCT07387198

Phase 3Q1 2030fianlimabNon-small Cell Lung CancerNCT05800015

Phase 3Q1 2030PozelimabParoxysmal Nocturnal HemoglobinuriaNCT07154745

Phase 3Q1 2030REGN7508Cancer-Associated Thrombosis (CAT)NCT07410117

Phase 2Q1 2030REGN10597Melanoma, Clear-Cell Renal-Cell Carcinoma (cc RCC), Advanced Solid TumorsNCT06413680

Phase 2Q1 2030ALN-PNPMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)NCT07527910

Phase 2Q1 2030REGN4336Metastatic Castration-resistant Prostate CancerNCT05125016

Phase 2Q2 2030OxaliplatinColorectal CancerNCT07281768

Phase 3Q2 2030CemiplimabCutaneous Squamous Cell Carcinoma (CSCC)NCT06585410

Phase 2Q2 2030UbamatamabAdvanced/Metastatic Non-Small Cell Lung CancerNCT07154290

Phase 2Q3 2030MaaT033 capsuleNSCLC (Advanced Non-small Cell Lung Cancer)NCT07001618

Phase 2Q4 2030REGN15505Metastatic Castration-Resistant Prostate Cancer (m CRPC), Clear Cell Renal Cell Carcinoma (cc RCC)NCT07594106

Phase 2Oct 31, 2030ZIV-AfliberceptMetastatic Uveal MelanomaNCT06121180

Phase 3Q2 2031OdronextamabRelapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)NCT06149286

Phase 3May 1, 2031OdronextamabB-cell Non Hodgkin LymphomaNCT05991388

Phase 2Jul 5, 2031CemiplimabLocally Advanced Basal Cell Carcinoma, Basal Cell CarcinomaNCT05929664

Phase 3Q3 2031REGN7508Venous Thromboembolism (VTE)NCT07493304

Phase 2Q1 2032ALN-SODAmyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) GeneNCT06351592

Primary: Incidence of Treatment-Emergent Adverse Event (TEAEs) in participants treated with ALN-SOD (At week 4 and through week 228)Enrollment:Target 42Sites: 16RANDOMIZED, TREATMENT

Phase 2Q2 2032REGN5093NSCLCNCT04077099

Phase 2Q2 2032LinvoseltamabMonoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)NCT06140524

Phase 2Q3 2032CemiplimabHigh-Grade Glioma (HGG), Posterior Fossa-A EpendymomaNCT07567469

Phase 2Dec 2, 2032LinvoseltamabMultiple MyelomaNCT06910124

Primary: Minimum Residual Disease Negative Conversion Rate (12 months)Enrollment:Target 32Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Q1 2033LinvoseltamabSmoldering Multiple Myeloma (SMM)NCT05955508

Phase 2Q1 2033LinvoseltamabMultiple MyelomaNCT03761108

Phase 3Q2 2033LinvoseltamabRelapsed Refractory Multiple Myeloma (RRMM)NCT05730036

Phase 3Q3 2033LinvoseltamabHigh Risk Smoldering Multiple Myeloma (HR-SMM)NCT07393282

Phase 2Q3 2033LinvoseltamabRelapsed Refractory Multiple Myeloma (RRMM)NCT07455851

Primary: Occurrence of Dose Limiting Toxicities (DLTs) from the first dose of REGN17372 in combination with linvoseltamab (Up to 35 days)Enrollment:Target 150Sites: 2NON_RANDOMIZED, TREATMENT

Phase 2Q4 2033LinvoseltamabRelapsed/Refractory Multiple MyelomaNCT06669247

Phase 2Q3 2034REGV131Hemophilia BNCT06379789

Phase 2Q4 2035LinvoseltamabMultiple MyelomaNCT05828511

Primary: Incidence of Dose-Limiting Toxicities (DLTs) (End of the Observation period; up to day 28)Enrollment:Target 149Sites: 32NON_RANDOMIZED, TREATMENT

Phase 3Q4 2036LinvoseltamabMultiple MyelomaNCT06932562

Phase 2TBDREGN475OsteoarthritisNCT01239017

Primary: The incidence of treatment-emergent adverse events (TEAEs) in patients treated with REGN475 or placebo. (16 weeks)0RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2TBDRilonaceptChronic Kidney Disease, AnemiaNCT00609544

Primary: Change in blood hemoglobin concentration. (Baseline to Week 12)0Sites: 27RANDOMIZED, TRIPLE, TREATMENT

Phase 2TBDR475Thermal Injury PainNCT01053702

Primary: Change in procedural pain intensity0Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Regeneron Pharmaceuticals Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research